Clinical trial results:
A Phase 2a Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Bris10 M2SR (H3N2 A/Brisbane/10/2007) Vaccine Administered as a Single Intranasal Dose (Versus Placebo) in Healthy Adult Volunteers who are Subsequently Challenged with a Live, Antigenically Different Wild-type Influenza Type A Virus (A/Belgium/4217/2015 H3N2)

Summary

EudraCT number	2017-004971-30
Trial protocol	BE
Global end of trial date	06 March 2019

Results information

Result version number	v1 (current)
This version publication date	19 March 2020
First version publication date	19 March 2020

Trial information

Trial identification

Sponsor protocol code	FLUGEN-H3N2-V002

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	FluGen Inc.
Sponsor organisation address	597 Science Drive, Madison, United States, WI USA 53711
Public contact	Pamuk Bilsel, FluGen, Inc, 001 608-442-6562, pbilsel@flugen.com
Scientific contact	Pamuk Bilsel, FluGen, Inc, 001 608-442-6562, pbilsel@flugen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 March 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	06 March 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

• Assess the effect of vaccination with Bris10/2007 M2SR (H3N2) vaccine on influenza viral shedding after intranasal challenge with a drifted H3N2 virus, A/Belgium/4217/2015.
• Assess the safety of the Bris10 M2SR (H3N2) vaccine during the period from study vaccine administration until influenza virus challenge.

Protection of trial subjects:

This study was conducted in compliance with the protocol, the ICH Note for Guidance on Good Clinical Practice (CMPM/ICH/135/95) and with the applicable regulatory requirement(s)

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 May 2018
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 108
Worldwide total number of subjects	108
EEA total number of subjects	108

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	108

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted in the SGS clinical pharmacology phase 1 unit in Antwerp, Belgium.

Pre-assignment

Screening details:

Screening for eligible, healthy male and non-pregnant female subjects who were 18 to 55 years old was performed within approximately 7 weeks prior to randomization/vaccine administration. A total of 108 subjects were randomized into the study and were vaccinated (56 placebo, 52 Bris10 M2SR), according to randomization.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Blinding implementation details:

All subjects underwent the same procedures. The unblinded pharmacy staff or delegate prepared doses (active and placebo), filled delivery devices, and applied an opaque label to the device barrel to obscure any coloration of the contents. The unblinded site staff and unblinded monitor agreed in writing to maintain the blind by not providing details of the dose (active or placebo) to any blinded clinic staff including the investigator or any study subjects.

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Subjects randomized to and receiving placebo

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal spray
Routes of administration	Intranasal use

Dosage and administration details:

The reference product (placebo) used in this study was a physiological saline suitable for intranasal delivery. Commercially available supplies of placebo (0.9% NaCl 10 mL) were used and supplied by the site following approval from the Sponsor. The placebo was drawn into a nasal sprayer for intranasal delivery. Doses of placebo were administered according to the same procedures as Bris10 M2SR vaccine.

Arm title	BRIS10 M2SR

Arm description:

Subjects randomized to and receiving BRIS10 M2SR

Arm type	Experimental
Investigational medicinal product name	FluGen’s H3N2 (A/Brisbane/10/2007) M2SR Vaccine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal spray
Routes of administration	Intranasal use

Dosage and administration details:

The vaccine was provided frozen and in single-use cryovials. An unblinded pharmacist thawed the vial contents to room temperature just prior to dose administration. The contents were diluted to the dosing

concentration with provided diluent for each subject. The final diluted product was drawn into a nasal sprayer for intranasal delivery.

Number of subjects in period 1	Placebo	BRIS10 M2SR
Started	56	52
Completed	51	48
Not completed	5	4
Consent withdrawn by subject	1	-
due to excl criteria 1 in part B	4	3
Due to bed capacity	-	1

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description: Subjects randomized to and receiving placebo	
Reporting group title	BRIS10 M2SR
Reporting group description: Subjects randomized to and receiving BRIS10 M2SR	

Reporting group values	Placebo	BRIS10 M2SR	Total
Number of subjects	56	52	108
Age categorical Units: Subjects			
Adults (18-55 years)	56	52	108
Age continuous Units: years			
arithmetic mean	38.9	39.6	
standard deviation	± 11.84	± 9.68	-
Gender categorical Units: Subjects			
Female	21	21	42
Male	35	31	66
Race Units: Subjects			
Asian	0	1	1
Black or African American	1	1	2
White	55	50	105
Ethnicity Units: Subjects			
Not Hispanic or Latino	56	52	108
Age categorical Units: Subjects			
Age ≤ 50 yrs	44	44	88
Age > 50 yrs	12	8	20
Smoking status Units: Subjects			
Ex-Smoker	13	16	29
Non-Smoker	42	34	76
Smoker	1	2	3
Age continuous Units: years			
median	40.0	40.5	
			-

Weight - 2 Units: kg median full range (min-max)	 73.4 52.3 to 106.8	 72.1 49.7 to 122.0	 -
BMI - 1 Units: kg/m2 arithmetic mean standard deviation	 24.29 ± 2.919	 24.37 ± 3.218	 -
BMI - 2 Units: kg/m2 median full range (min-max)	 24.61 19.07 to 30.54	 23.81 18.66 to 30.96	 -

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Subjects randomized to and receiving placebo	
Reporting group title	BRIS10 M2SR
Reporting group description:	
Subjects randomized to and receiving BRIS10 M2SR	

Primary: Summary of qRT-PCR Viral Load Following Challenge (FAS) - AUC - 1

End point title	Summary of qRT-PCR Viral Load Following Challenge (FAS) - AUC - 1[1]
End point description:	
Primary endpoint 1: Area under the curve (AUC) of the influenza RNA log10 viral load by qRT-PCR from nasopharyngeal swabs of study subjects in the vaccine and placebo groups.	
End point type	Primary
End point timeframe:	
From the time of challenge inoculation with A/Belgium/4217/2015 until discharge (10 days after inoculation).	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There were no pre-specified tests of hypotheses. Analyses were descriptive summaries of results.

End point values	Placebo	BRIS10 M2SR		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	48		
Units: n, n Missing				
AUC (n)	51	48		
AUC (n Missing)	0	0		
ln(AUC) (n)	51	48		
ln(AUC) (n Missing)	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Summary of qRT-PCR Viral Load Following Challenge (FAS) - AUC - 2

End point title	Summary of qRT-PCR Viral Load Following Challenge (FAS) - AUC - 2[2]
End point description:	
Primary endpoint 1: Area under the curve (AUC) of the influenza RNA log10 viral load by qRT-PCR from nasopharyngeal swabs of study subjects in the vaccine and placebo groups.	
End point type	Primary
End point timeframe:	
From the time of challenge inoculation with A/Belgium/4217/2015 until discharge (10 days after	

inoculation).

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There were no pre-specified tests of hypotheses. Analyses were descriptive summaries of results.

End point values	Placebo	BRIS10 M2SR		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	48		
Units: Viral load				
arithmetic mean (standard deviation)				
AUC	513.85 (± 444.798)	423.99 (± 420.644)		
ln(AUC)	5.11 (± 2.348)	4.78 (± 2.296)		

Statistical analyses

No statistical analyses for this end point

Primary: Summary of qRT-PCR Viral Load Following Challenge (FAS) - AUC - 3

End point title	Summary of qRT-PCR Viral Load Following Challenge (FAS) - AUC - 3[3]

End point description:

Primary endpoint 1: Area under the curve (AUC) of the influenza RNA log10 viral load by qRT-PCR from nasopharyngeal swabs of study subjects in the vaccine and placebo groups.

End point type	Primary

End point timeframe:

From the time of challenge inoculation with A/Belgium/4217/2015 until discharge (10 days after inoculation).

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There were no pre-specified tests of hypotheses. Analyses were descriptive summaries of results.

End point values	Placebo	BRIS10 M2SR		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	48		
Units: Viral load				
median (full range (min-max))				
AUC	501.33 (0.00 to 1404.25)	303.23 (0.00 to 1216.12)		
ln(AUC)	6.22 (0.00 to 7.25)	5.71 (0.00 to 7.10)		

Statistical analyses

No statistical analyses for this end point

Primary: Overall Summary of Adverse Events – Vaccine Period (Safety Set) - 1

End point title	Overall Summary of Adverse Events – Vaccine Period (Safety Set) - 1[4]

End point description:

Primary endpoint 2: Number of study subjects reporting solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs)

End point type	Primary

End point timeframe:

From the time of administration of the vaccine or placebo until administration of challenge virus.

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There were no pre-specified tests of hypotheses. Analyses were descriptive summaries of results.

End point values	Placebo	BRIS10 M2SR		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	56	52		
Units: Number of subjects				
# Subjects with at least 1 TEAE	34	32		
# Subjects with at least 1 TEAE related to vaccine	28	21		

Statistical analyses

No statistical analyses for this end point

Primary: Overall Summary of Adverse Events – Vaccine Period (Safety Set) - 2

End point title	Overall Summary of Adverse Events – Vaccine Period (Safety Set) - 2[5]

End point description:

Primary endpoint 2: Proportions of study subjects reporting solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs).

End point type	Primary

End point timeframe:

From the time of administration of the vaccine or placebo until administration of challenge virus.

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: There were no pre-specified tests of hypotheses. Analyses were descriptive summaries of results.

End point values	Placebo	BRIS10 M2SR		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	56	52		
Units: % of Subjects				
% Subjects with at least 1 TEAE	61	62		
% Subjects with at least 1 TEAE related to vaccine	50	40		

Statistical analyses

No statistical analyses for this end point

Secondary: Summary of Overall Infection and Influenza Illness (Full Analysis Set)

End point title	Summary of Overall Infection and Influenza Illness (Full Analysis Set)

End point description:

Secondary endpoint: the proportion of study subjects in vaccine and placebo groups with infection following challenge with A/Belgium/4217/2015 as determined by qRT-PCR.2 and the proportion of study subjects in vaccine and placebo groups with infection AND influenza illness following intranasal challenge with A/Belgium/4217/2015.
- Infection is defined as at least two consecutive qRT-PCR positive swabs starting on the second day after challenge (Day 3).
- Influenza illness is defined as either at least one respiratory symptom on two consecutive days OR at least one respiratory and at least one systemic symptom on two consecutive days.

End point type	Secondary

End point timeframe:

During the trial

End point values	Placebo	BRIS10 M2SR		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	51	48		
Units: Number of Subjects				
Infected	36	26		
Influenza illness	29	23		
Infected and Influenza illness	25	16		

Statistical analyses

Statistical analysis title	Proportion of subjects infected
Comparison groups	Placebo v BRIS10 M2SR
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other[6]
P-value	= 0.10133
Method	Fisher exact

Notes:

[6] - Descriptive

Statistical analysis title	Proportion of subjects with Influenza illness

Comparison groups	Placebo v BRIS10 M2SR
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other[7]
P-value	= 0.42383
Method	Fisher exact

Notes:

[7] - Descriptive

Statistical analysis title	Proportion of subjects infected &Influenza illness
Comparison groups	Placebo v BRIS10 M2SR
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	other[8]
P-value	= 0.15316
Method	Fisher exact

Notes:

[8] - Descriptive

Secondary: Treatment-Emergent Adverse Events (TEAE)

End point title	Treatment-Emergent Adverse Events (TEAE)

End point description:

Secondary endpoint: Number (+%) of study subjects reporting treatment-emergent solicited and unsolicited AEs and SAEs.

End point type	Secondary

End point timeframe:

During the study

End point values	Placebo	BRIS10 M2SR		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	56	52		
Units: Number (+%) of subjects				
Nbr of subjects with any TEAE	34	32		
% of subjects with any TEAE	61	62		
Nbr of subjects with any vaccine related TEAE	28	21		
% of subjects with any vaccine related TEAE	50	40		

Statistical analyses

No statistical analyses for this end point

Secondary: Challenge-Emergent Adverse Events (CEAE)

End point title	Challenge-Emergent Adverse Events (CEAE)

End point description:	
Secondary endpoint: Number (+%) of study subjects reporting challenge -emergent solicited and unsolicited AEs and SAEs.	
End point type	Secondary
End point timeframe:	
During the study	

End point values	Placebo	BRIS10 M2SR		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	56	52		
Units: Number and % of subjects				
Nbr of subjects with any CEAE	39	36		
% of subjects with any CEAE	76	75		
Nbr of subjects with any innoculation related CEAE	37	34		
% of subjects with any innoculation related CEAE	73	71		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events are monitored continuously from day of IP treatment until the last study-related activity (typically Day 28)

Adverse event reporting additional description:

At regular intervals during the study, subjects will be asked non-leading questions to determine the occurrence of any AEs. All AEs reported spontaneously during the course of the study will be recorded as well. Solicited and unsolicited signs and symptoms will be reported as AEs after review by the Investigator or designee.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.0

Reporting groups

Reporting group title	Placebo - TEAE

Reporting group description:

Subjects randomized to and receiving placebo

Reporting group title	BRIS10 M2SR - TEAE

Reporting group description:

Subjects randomized to and receiving BRIS10 M2SR

Reporting group title	Placebo - CEAE

Reporting group description: -

Reporting group title	BRIS10 M2SR - CEAE

Reporting group description: -

Serious adverse events	Placebo - TEAE	BRIS10 M2SR - TEAE	Placebo - CEAE
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	BRIS10 M2SR - CEAE		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 48 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo - TEAE	BRIS10 M2SR - TEAE	Placebo - CEAE
Total subjects affected by non-serious adverse events			
subjects affected / exposed	34 / 56 (60.71%)	32 / 52 (61.54%)	39 / 51 (76.47%)
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	6 / 56 (10.71%)	4 / 52 (7.69%)	0 / 51 (0.00%)
occurrences (all)	1	1	0
Malaise			
subjects affected / exposed	2 / 56 (3.57%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Chills			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Influenza like illness			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	34 / 51 (66.67%)
occurrences (all)	0	0	1
Vessel puncture site haematoma			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Feeling hot			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	4 / 51 (7.84%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	9 / 56 (16.07%)	7 / 52 (13.46%)	1 / 51 (1.96%)
occurrences (all)	1	1	1
Rhinorrhoea			

subjects affected / exposed	9 / 56 (16.07%)	8 / 52 (15.38%)	0 / 51 (0.00%)
occurrences (all)	1	1	0
Cough			
subjects affected / exposed	4 / 56 (7.14%)	2 / 52 (3.85%)	0 / 51 (0.00%)
occurrences (all)	1	1	0
Throat irritation			
subjects affected / exposed	4 / 56 (7.14%)	6 / 52 (11.54%)	0 / 51 (0.00%)
occurrences (all)	1	1	0
Respiratory tract irritation			
subjects affected / exposed	1 / 56 (1.79%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Sneezing			
subjects affected / exposed	1 / 56 (1.79%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	1	0	1
Epistaxis			
subjects affected / exposed	0 / 56 (0.00%)	2 / 52 (3.85%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Investigations			
Hepatic enzyme increased			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fracture			
subjects affected / exposed	1 / 56 (1.79%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Arthropod bite			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Ligament sprain			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Skin wound			

subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Injury			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Headache			
subjects affected / exposed	16 / 56 (28.57%)	11 / 52 (21.15%)	1 / 51 (1.96%)
occurrences (all)	1	1	1
Dysgeusia			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Blood and lymphatic system disorders			
Lymphadenopathy			
subjects affected / exposed	1 / 56 (1.79%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	1	1	0
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	1 / 56 (1.79%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Vertigo			
subjects affected / exposed	1 / 56 (1.79%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	1 / 56 (1.79%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	1	1	0
Constipation			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Tooth disorder			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Toothache			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Vomiting			

subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Diarrhoea			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	1 / 51 (1.96%)
occurrences (all)	0	0	1
Abdominal discomfort			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Hyperhidrosis			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	0 / 56 (0.00%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	3 / 56 (5.36%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	3	0	0
Musculoskeletal stiffness			
subjects affected / exposed	2 / 56 (3.57%)	0 / 52 (0.00%)	0 / 51 (0.00%)
occurrences (all)	1	0	0
Back pain			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	0 / 56 (0.00%)	1 / 52 (1.92%)	0 / 51 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			

Nasopharyngitis subjects affected / exposed		1 / 52 (1.92%)	1 / 51 (1.96%)

subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Throat irritation			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Respiratory tract irritation			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Sneezing			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Epistaxis			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Investigations			

Hepatic enzyme increased			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Fracture			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Arthropod bite			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Ligament sprain			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Skin wound			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Injury			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Lymphadenopathy			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Vertigo			

subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Tooth disorder			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Abdominal discomfort			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Stomatitis			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Hyperhidrosis			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Rash			

subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Musculoskeletal stiffness			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Back pain			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Oral herpes			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Herpes simplex			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 48 (0.00%)		
occurrences (all)	0		
Fungal skin infection			
subjects affected / exposed	1 / 48 (2.08%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported